Celcuity Inc. CELC

CELC Company Overview

Celcuity Inc. is a U.S.-based clinical-stage biotechnology company focused on developing targeted therapies for cancer. The company operates within the oncology and precision medicine industries, with a strategic emphasis on treating solid tumors driven by aberrant signaling pathways. Celcuity’s primary value driver is the development of kinase inhibitor therapies intended to address resistance mechanisms in hormone receptor-positive and HER2-negative breast cancer, as well as other tumor types with pathway dysregulation. Its lead asset, gedatolisib, is an investigational pan-PI3K/mTOR inhibitor being evaluated in multiple clinical programs. The company also historically developed proprietary diagnostic and cellular signaling pathway analysis technologies, although its strategic focus has shifted primarily toward therapeutic drug development.

Celcuity was founded in 2012 and is headquartered in Minneapolis, Minnesota. The company evolved from a diagnostics-oriented biotechnology platform into a therapeutics-focused oncology company following the acquisition and advancement of gedatolisib from Pfizer Inc. Public filings and investor materials indicate that Celcuity’s strategy centers on combining targeted therapies with endocrine treatments and CDK4/6 inhibitors to improve outcomes in difficult-to-treat breast cancer populations. Its positioning is differentiated by its focus on biologically validated signaling pathways and combination treatment approaches intended to overcome acquired resistance in cancer therapy.